Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

Monotherapy in immunotherapy-ineligible patients improved median PFS to 9.7 vs 6.9 months versus physician’s-choice chemotherapy, with 50% vs 47% objective response rates. Combination therapy in PD-L1 ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey By Michael ...

Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...

Dec 2 (Reuters) - U.S. drugmaker Merck & Co (MRK.N), opens new tab hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it ...